Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MeDSuN Pilot Phase II Ready To Start In February; Reg Is 2-3 Years Away

This article was originally published in The Gray Sheet

Executive Summary

FDA anticipates that beta testing of its MeDSuN Internet-based surveillance system will begin the week of Jan. 21, as software and hardware development is now complete

You may also be interested in...



Expanded MedSun Surveillance Network Highlighted By FDA; Funding Planned

FDA intends to allocate $34 mil. to its Medical Product Surveillance Network (MedSun) in FY 2006, with the goal of recruiting 350 facilities into the program

Expanded MedSun Surveillance Network Highlighted By FDA; Funding Planned

FDA intends to allocate $34 mil. to its Medical Product Surveillance Network (MedSun) in FY 2006, with the goal of recruiting 350 facilities into the program

M-DEN Event Reporting Forum To Join FDA’s MedSun Pilot

FDA will add a Medical Device Engineering Network (M-DEN) to its MedSun adverse event pilot, providing an interactive forum for device information exchange

Related Content

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel